- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.05. | AB&B BIO-TECH-B (02627): VOLUNTARY ANNOUNCEMENT - COMMENCEMENT OF PHASE I AND PHASE II CLINICAL TRIALS FOR RECOMBINANT RSV VACCINE (CHO CELL) (ADJUVANT) | 1 | HKEx | ||
| 11.05. | AB&B BIO-TECH-B mRNA RSV Vaccine Approved for Clinical Trials in Mainland China | 1 | AASTOCKS | ||
| 08.05. | AB&B BIO-TECH-B (02627): VOLUNTARY ANNOUNCEMENT - IND APPROVAL BY CHINA CDE FOR MRNA RSV VACCINE | 1 | HKEx | ||
| 08.05. | AB&B BIO-TECH-B (02627): FORM OF PROXY FOR THE FIRST EXTRAORDINARY GENERAL MEETING OF 2026 TO BE HELD ON WEDNESDAY, MAY 27, 2026 AND ANY ADJOURNMENT THEREOF | 2 | HKEx | ||
| 08.05. | AB&B BIO-TECH-B (02627): (1) ABOLITION OF THE SUPERVISORY COMMITTEE (2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION (3) AMENDMENTS TO CERTAIN INTERNAL CORPORATE ... | 1 | HKEx | ||
| AB&B BIO-TECH Aktie jetzt für 0€ handeln | |||||
| 07.05. | AB&B BIO-TECH-B (02627): NOTICE OF THE FIRST EXTRAORDINARY GENERAL MEETING OF 2026 | - | HKEx | ||
| 29.04. | AB&B BIO-TECH-B (02627): RESUMPTION GUIDANCE AND CONTINUED SUSPENSION OF TRADING | - | HKEx | ||
| 24.04. | AB&B BIO-TECH-B (02627): (I) NOMINATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR (II) CHANGE OF BOARD COMMITTEE MEMBERS AND (III) PROPOSED AMENDMENTS TO ... | - | HKEx | ||
| 24.04. | AB&B BIO-TECH-B (02627): PROPOSED APPOINTMENT OF AUDITOR | 3 | HKEx | ||
| 14.04. | AB&B BIO-TECH-B (02627): PROPOSED CHANGE OF AUDITOR | 1 | HKEx | ||
| 01.04. | AB&B BIO-TECH-B (02627): INSIDE INFORMATION: (1) DELAY IN PUBLICATION OF ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025; (2) POSTPONEMENT ... | 1 | HKEx | ||
| 19.03. | AB&B BIO-TECH-B (02627): DATE OF BOARD MEETING | 1 | HKEx | ||
| 13.03. | AB&B BIO-TECH-B (02627): VOLUNTARY ANNOUNCEMENT - ENTERING INTO OF STRATEGIC COOPERATION AGREEMENT | 1 | HKEx | ||
| 04.03. | AB&B BIO-TECH-B (02627): VOLUNTARY ANNOUNCEMENT - IND APPROVAL BY U.S. FDA FOR MRNA MPOX VACCINE | 1 | HKEx | ||
| 26.02. | AB&B BIO-TECH-B (02627): PROFIT ALERT - EXPECTED REDUCTION IN LOSS | 2 | HKEx | ||
| 16.02. | AB&B BIO-TECH-B (02627): VOLUNTARY ANNOUNCEMENT - INCLUSION AS A CONSTITUENT OF HANG SENG COMPOSITE INDEX | 3 | HKEx | ||
| 30.01. | AB&B BIO-TECH-B (02627): VOLUNTARY ANNOUNCEMENT - APPROVAL OF OUR APPLICATION FOR TRIVALENT SUBUNIT INFLUENZA VACCINE BY THE NMPA | - | HKEx | ||
| 12.01. | AB&B BIO-TECH-B (02627): (1) RESIGNATION OF NON-EXECUTIVE DIRECTOR; AND (2) RESIGNATION OF BOARD SECRETARY AND JOINT COMPANY SECRETARY | - | HKEx | ||
| 23.12.25 | AB&B BIO-TECH-B (02627): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 23.12.25 | AB&B BIO-TECH-B (02627): (1) POLL RESULTS OF THE SECOND EXTRAORDINARY GENERAL MEETING OF 2025 (2) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND ... | 1 | HKEx |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 29,815 | -0,32 % | QIAGEN N.V.: QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA | Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights' curated biomedical knowledge bases Goal to advance how disease mechanisms... ► Artikel lesen | |
| RELAY THERAPEUTICS | 14,430 | +10,83 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Pricing of Public Offering of Common Stock | CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies... ► Artikel lesen | |
| EVOTEC | 4,944 | +0,90 % | Evotec-Aktie mit -11% Einbruch - Panik nimmt weiter zu | Die Evotec-Aktie ist gestern -10,63% eingebrochen und geriet damit erneut massiv unter Druck. Nach einer zuvor kurzfristigen Stabilisierung verschlechterte sich das Chartbild wieder, während wichtige... ► Artikel lesen | |
| IMMUNOVANT | 35,500 | -0,17 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| BIONTECH | 77,90 | +0,19 % | Ihre wichtigsten Termine: Alle Blicke auf: Fraport, Biontech, Nagarro, Freenet & Intercontinental Exchange | © Foto: UnsplashGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00 Uhr, Deutschland:... ► Artikel lesen | |
| IMMIX BIOPHARMA | 9,250 | +3,58 % | Immix Biopharma, Inc.: Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2 | - Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) - - CR rate now 95% (19 of 20 patients) - - All CRs reached within 1 year of follow-up post-dosing... ► Artikel lesen | |
| BEAM THERAPEUTICS | 26,700 | -1,51 % | Beam Therapeutics presents AATD gene therapy trial data at ATS | ||
| SUMMIT THERAPEUTICS | 17,690 | -1,12 % | H.C. Wainwright Reduced its Price Goal on Summit Therapeutics Inc. (SMMT) | ||
| CG ONCOLOGY | 65,37 | +0,93 % | CG Oncology Inc.: CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat... ► Artikel lesen | |
| ERASCA | 11,160 | +0,36 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| TANGO THERAPEUTICS | 21,360 | +1,33 % | Tango Therapeutics Shares Fall 17% | ||
| INHIBRX BIOSCIENCES | 106,10 | -3,55 % | Inhibrx Biosciences, Inc.: Inhibrx Reports First Quarter 2026 Financial Results | SAN DIEGO, May 14, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter... ► Artikel lesen | |
| MODERNA | 40,810 | -1,40 % | Roivant anticipates $950M Moderna payment in July as it outlines 2H 2026 mosliciguat and IMVT-1402 readouts | ||
| PROTAGONIST THERAPEUTICS | 100,04 | -0,83 % | Hedge Fund and Insider Trading News: Bill Ackman, Seth Klarman, David Einhorn, Michael Burry, Perbak Capital Partners, Charter Communications Inc (CHTR), Protagonist Therapeutics Inc (PTGX), and More | ||
| STRUCTURE THERAPEUTICS | 37,380 | +1,33 % | Structure Therapeutics Inc.: Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel | SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen |
Das Unternehmen AB&B BIO-TECH CO LTD JS kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AB&B BIO-TECH CO LTD JS finden Sie auf Wallstreet Online.